Rosetta Genomics' Q1 Loss Nearly Doubles | GenomeWeb
NEW YORK (GenomeWeb News) – Rosetta Genomics today reported that its first-quarter net loss nearly doubled year over year as the firm gears up for initial diagnostic product launches.
 
The Rehovot, Israel-based firm had no revenues for the three-month period ended March 31. The firm expects to have its initial microRNA-based diagnostic tests for cancer approved for use in CLIA labs by the end of this year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.